Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 70/100

Failure Rate

10.0%

1 terminated/withdrawn out of 10 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

10%

1 trials in Phase 3/4

Results Transparency

0 of 0 completed trials have results

Key Signals

4 recruiting

Enrollment Performance

Analytics

Phase 2

3(42.9%)

N/A

3(42.9%)

Phase 4

1(14.3%)

7Total

Phase 2(3)

N/A(3)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (10)

Showing 10 of 10 trials

NCT07128251Phase 2Not Yet Recruiting

A Single-Arm, Multicenter, Exploratory Clinical Study of Transarterial Chemoembolization (TACE) Combined With Iparomlimab and Tuvonralimab Injection and Bevacizumab Injection for the Treatment of Unresectable, Non-Metastatic Hepatocellular Carcinoma (HCC)

Role: collaborator

NCT06863831Not ApplicableEnrolling By Invitation

A Multicenter Trial of YSQTG vs. Simulated Agents With Neoadjuvant Chemoradiotherapy or Chemoimmunotherapy for EC

Role: collaborator

NCT06440018Recruiting

INSPIRE: a Multi-Cancer Early Detection Study

Role: collaborator

NCT06553352Phase 2Recruiting

Zanubrutinib in Combination With Obinutuzumab (ZO) for Newly Diagnosed Follicular Lymphoma

Role: collaborator

NCT06478472Not ApplicableRecruiting

Prospective Clinical Study of Orelabrutinib in Combination With Rituximab (OR) for Primary Marginal Zone Lymphoma (MZL) That Failed or Not Suitable for Local Therapy

Role: collaborator

NCT04923802Terminated

Multi-Omics Testing for Immunotherapy Efficacy Evaluation (MOTIVATION)

Role: collaborator

NCT05411705Phase 4Recruiting

Efficacy and Safety of rhTPO's Prophylactic Treatment of CTIT in Patients With High Risk of Cardiac Injury

Role: collaborator

NCT05900921Phase 2Unknown

Trilaciclib Prior to Chemotherapy Plus Tislelizumab as 1L Treatment for Advanced Squamous Non-Small-Cell Lung Cancer

Role: collaborator

NCT05816642Not ApplicableUnknown

Application Circulating Tumor DNA Dynamic Monitoring in Clinical Treatment of Metastatic Renal Cell Carcinoma